EUVIMEDEUVIMED entdecken
Crossref

Efavirenz Mitigates Dyslipidemia and Attenuates Ulcerative Colitis through Gut Microbiota Modulation

Wei Wang iD, Xiaoge Niu iD, Shasha Li, Binbin Cheng iD, Luping Cheng, Chan Yang, Xinfeng Xu iD, Siqiao Chang, Chan Wang, Shuwen Liu iD

ACS Infectious Diseases · 12.06.2026 · 12 (6) · 2136-2148

DOI: 10.1021/acsinfecdis.6c00330 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Infectious Diseases, online erschienen am 01.06.2026. Verfasst von Wei Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China. Hauptthemen laut MEDLINE: Benzoxazines, Dyslipidemias, Gastrointestinal Microbiome, Colitis, Ulcerative. Die Arbeit nennt 72 Literaturangaben. Gefördert von: Guangdong Provincial Department of Science and Technology, Basic and Applied Basic Research Foundation of Guangdong Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzoxazinesDyslipidemiasGastrointestinal MicrobiomeColitis, UlcerativeAlkynesAnimalsCyclopropanesHumansRatsMaleDiet, High-FatDisease Models, AnimalHIV InfectionsRats, Sprague-DawleyOxidoreductases Acting on CH-CH Group Donors

Stichwörter der Autor:innen

7-dehydrocholesterol reductaseDyslipidemiaEfavirenzGut microbiotaUlcerative colitis

Substanzen

AlkynesBenzoxazinesCyclopropanesefavirenz7-dehydrocholesterol reductaseOxidoreductases Acting on CH-CH Group Donors

Autor:innen und Institutionen

  • Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
  • Department of Pharmacy, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China.
  • Ribopeutic Inc., Guangzhou International Bio Island, Guangzhou 510005, China.
  • State Key Laboratory of Organ Failure Research, Guangdong Provincial Institute of Nephrology, Southern Medical University, Guangzhou 510515, China.
  • MOE Key Laboratory of Infectious Diseases Research in South China, Southern Medical University, Guangzhou 510515, China.

ORCID-Profile: Wei Wang, Xiaoge Niu, Binbin Cheng, Xinfeng Xu, Shuwen Liu

Förderung

  • Guangdong Provincial Department of Science and Technology
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • National Natural Science Foundation of China
  • Scientific and Technological Planning Project of Guangzhou City
  • National Health Commission Capacity Building and Continuing Education Center

Zitieren

APA

Wang, W., Niu, X., Li, S., Cheng, B., Cheng, L., Yang, C., Xu, X., Chang, S., Wang, C., & Liu, S. (2026). Efavirenz Mitigates Dyslipidemia and Attenuates Ulcerative Colitis through Gut Microbiota Modulation. ACS Infectious Diseases, 12(6), 2136-2148. https://doi.org/10.1021/acsinfecdis.6c00330

Vancouver

Wang W, Niu X, Li S, Cheng B, Cheng L, Yang C, et al. Efavirenz Mitigates Dyslipidemia and Attenuates Ulcerative Colitis through Gut Microbiota Modulation. ACS Infectious Diseases. 2026;12(6):2136-2148. doi:10.1021/acsinfecdis.6c00330

BibTeX
@article{Wang2026,
  author = {Wang, Wei and Niu, Xiaoge and Li, Shasha and Cheng, Binbin and Cheng, Luping and Yang, Chan and Xu, Xinfeng and Chang, Siqiao and Wang, Chan and Liu, Shuwen},
  title = {Efavirenz Mitigates Dyslipidemia and Attenuates Ulcerative Colitis through Gut Microbiota Modulation},
  journal = {ACS Infectious Diseases},
  year = {2026},
  volume = {12},
  number = {6},
  pages = {2136--2148},
  doi = {10.1021/acsinfecdis.6c00330}
}
Kostenlos starten →